Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

NCT06487078 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

ALK+ Non-Small-Cell Lung Carcinoma

Interventions

DRUG: Lorlatinib

Sponsor

Pfizer